Jubilant Life Sciences’ arm to raise funds through Bonds

01 Mar 2019 Evaluate

Jubilant Life Sciences’ wholly-owned subsidiary -- Jubilant Pharma (JPL), a company incorporated under the laws of Singapore, has successfully priced its rated unsecured bonds at 6.00% per annum issued at par for $200 million maturing in March, 2024.

S&P Global Ratings (S&P) has affirmed ‘BB-/positive’ rating and Fitch Ratings (Fitch) has affirmed ‘BB-/Stable’ rating for JPL. The Notes have been rated ‘BB-’ by S&P and ‘BB’ by Fitch.

The major portion of the net proceeds of the Notes shall be used to refinance existing indebtedness and pay associated fees and premiums over a period of time and the balance amount for working capital and general corporate purposes.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

1062.45 -11.00 (-1.02%)
09-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.95
Dr. Reddys Lab 1209.45
Cipla 1466.15
Zydus Lifesciences 894.95
Lupin 2181.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×